Four Capabilities Redefining Competitive Advantage in Biologics CDMOs in 2026

The global biologics and advanced therapies market grew 9% year-over-year to $515 billion in 2025, extending a decade of sustained expansion. However, this growth is now unfolding within a volatile operating environment. Geopolitical fragmentation, shifting trade policies, tighter capital markets, and persistent supply chain bottlenecks are becoming structural constraints on how biologics manufacturing capacity is built, accessed, and deployed.

These pressures are forcing a structural shift in how the biologics CDMO sector operates. The expansion-led model of the past decade was characterized by large-scale capacity buildout and capital availability. However, this model is now giving way to a more constrained environment where competitive advantage depends on the ability to execute reliably. This shift requires biologics CDMO leaders to continuously reassess strategic decisions in response to shifting geopolitical conditions, growing need for specialized capabilities, and tighter capital constraints.

This article examines four strategic capabilities that are redefining competitive advantage in the biologics CDMO sector and are required to deliver reliable execution in an increasingly constrained and performance-driven environment:

1. Dedicated manufacturing capacity models for critical products
2. Geopolitically resilient manufacturing network design
3. AI-enabled operational performance capabilities
4. Disciplined, demand-linked capital deployment

1. Dedicated Manufacturing Capacity Models

Access to constrained manufacturing capacity is becoming a strategic differentiator, particularly in sterile drug-product manufacturing. As a result, capital is increasingly concentrated in these segments, with investment focused on debottlenecking to add effective rather than installed capacity and on securing dedicated access.

The Novo Holdings–Catalent transaction illustrates this structural shift in the biologics CDMO industry. This transaction showed how large biopharma is moving from reliance on shared CDMO capacity to securing dedicated, sponsor-controlled manufacturing infrastructure for critical products, reshaping how capacity is accessed and valued across the CDMO market. A central component of the transaction was the transfer of three sterile fill-finish facilities in Anagni (Italy), Brussels (Belgium), and Bloomington, Indiana (US) to Novo Nordisk.

These sites support large-scale injectable biologics, and their transfer reflects the growing strategic importance of securing dedicated sterile capacity for high-volume therapies, particularly GLP-1 treatments, where supply continuity directly influences commercial performance.

2. Geopolitically Resilient Network Design

Manufacturing geography is becoming a primary constraint in CDMO selection as sponsors incorporate geopolitical and trade policy considerations into commercial supply planning. US policy developments, including measures associated with the BIOSECURE framework, increase scrutiny of cross-border manufacturing linkages and reinforce the importance of regulatory alignment and long-term supply security.

As a result, North American and European manufacturing infrastructure is gaining strategic importance, particularly for late-stage and commercial biologics requiring a stable and jurisdictionally aligned supply. For example, the geographic distribution of biologics CDMO investments by country in 2025 reveals a striking concentration in the US, which captured $4,257 million in disclosed investment value. This represents approximately 77% of the total investment value.

This dynamic is reflected in the 2025 European Medicines Agency approval for commercial manufacturing at WuXi Biologics’ Dundalk, Ireland facility. The approval enabled an EU-based supply for globally developed assets and reduced reliance on non-aligned supply chains.

Sponsors continue to utilize Asian manufacturing capacity but are increasingly adopting geographically diversified sourcing strategies to reduce regional dependency and strengthen supply resilience.